Related Experiment Video
Updated: Sep 20, 2025
Mouse Models for Graft Arteriosclerosis
Published on: May 14, 2013
Cardiac allograft vasculopathy and the endothelial glycocalyx: a missing link?
Mitchell J Wagner1, Michael Khoury2, Jennifer Conway2
1Department of Surgery, University of Alberta, Edmonton, AB, Canada.
Insights
Cardiac allograft vasculopathy (CAV) is a leading cause of heart transplant graft loss. This review proposes that endothelial glycocalyx (EGX) damage links immune and non-immune factors, offering new therapeutic targets for CAV.
Area of Science:
- Cardiovascular Science
- Transplantation Immunology
- Vascular Biology
Background:
- Cardiac allograft vasculopathy (CAV) is a primary cause of graft failure after heart transplantation.
- Immune and non-immune factors contribute to CAV, but their mechanistic link is unclear.
- The endothelial glycocalyx (EGX) is a protective vascular layer potentially involved in CAV.
Purpose of the Study:
- To propose a novel model where EGX disturbance links immune and non-immune risk factors in CAV pathogenesis.
- To review current evidence on the role of EGX in CAV.
- To highlight potential new therapeutic strategies for CAV based on EGX preservation.
Main Methods:
- Literature review and synthesis of existing research on CAV and EGX.
- Development of a conceptual model linking EGX to CAV pathogenesis.
- Analysis of immune and non-immune risk factors in the context of EGX integrity.
Main Results:
- Evidence suggests EGX integrity is compromised in CAV.
- A cohesive mechanistic link between immune/non-immune factors and CAV via EGX disturbance is proposed.
- The proposed model highlights EGX as a central player in CAV development.
Conclusions:
- Disturbance of the endothelial glycocalyx may be a central mechanism in cardiac allograft vasculopathy.
- This novel model offers new perspectives for developing preventive and therapeutic strategies for CAV.
- Further research is warranted to validate the role of EGX in CAV and explore its therapeutic potential.
Abstract:
Cardiac allograft vasculopathy (CAV) is a significant contributor to graft loss following heart transplantation, with a linear cumulative incidence over time. Both immune and non-immune risk factors are associated with the development of CAV, however, a cohesive mechanistic link between them is yet to be established. Immune and non-immune risk factors may be linked to CAV via disturbance of the endothelial glycocalyx (EGX), a protective vascular structure whose functions appear to be impaired in the context of CAV progression. In this review, we present this hypothesis, summarizing the evidence and implications for EGX loss during CAV. We synthesize a novel model that places EGX disturbance at the center of CAV pathogenesis. As a currently incurable disease, we highlight that this new model may unlock new approaches to prevention and therapy and requires further research.
